Guardant Health, Inc. Common Stock (GH) Stock Analysis
Market Closed
Sector: Healthcare · Industry: Services-Medical Laboratories
AnalystsStrong Buy35 analystsWhat's happening with GH
Price History
5-Year Weekly Candlestick Chart
Profile
Strong financial health; profitability, valuation, growth and earnings quality lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-1.0%)0/25
- P/S (21.7x)0/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (27.3%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (n/a)0/25
- Net margin (-40.1%)0/25
- Operating margin (-41.4%)0/25
- Financial Health75/100 · Strong
- Altman Z (4.93)25/25
- Current ratio (4.68)25/25
- Interest coverage (-151.0x)0/25
- Net cash / debt (Net cash)25/25
- Quality40/100 · Weak
- Piotroski F (5/9)15/25
- Beneish M (-3.21)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 31.9%)0/25
About Guardant Health, Inc. Common Stock
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. Show more
The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Headquarters: PALO ALTO, CA · Employees: 2,506 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellGift · filed 2026-08-27-30000 sh2026-08-26
- BuyJ · filed 2026-08-27+25.0K sh2026-08-26
- SellJ · filed 2026-08-27-25000 sh2026-08-26
- SellOpen market sale · filed 2026-08-24-7589 sh2026-08-21
- SellOpen market sale · filed 2026-08-24-20888 sh2026-08-21
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-1.0%D
Grade D: NegativeTTM FCF / Market Cap — vs own 5Y history: -19.4%–-1.0% · highest in history
P/S (TTM)21.75xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.2x–40.1x · 93rd pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales20.2xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B RatioNeg. EquityC
Grade C: BuybacksPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-11.01A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROENeg. EquityC
Grade C: BuybacksReturn on Equity. Neg. equity = heavy buybacks
ROA-25.5%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-40.1%D
Grade D: LowNet Income / Revenue
Operating Margin-41.4%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin64.9%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-22.0%D
Grade D: LowFCF / Revenue
True FCF Margin-38.3%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
75B+Altman Z-Score4.93A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.68xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio4.42xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-151.0xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity—
Debt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Growth
25ERevenue CAGR27.3%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue16.3%D
Grade D: HighTTM stock-based comp / TTM Revenue
Quality
8/8 Loss Years40D+Piotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-3.21A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability31.9%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue4.6%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.49xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$9.20
Cash & short-term investments per share (Finnhub)
Book Value / Share$1.30
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$1.10B
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$-181.07M
Shareholders' equity (book value)
Asset / Liability0.91xD
Grade D: RiskyTotal Assets / Total Liabilities
Market
Market Cap$23.49B
Current Market Capitalization
Beta1.73C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Robust financial health and a strong balance sheet are offset by a lack of profitability and negative free cash flow, while the company's valuation trades at an elevated level relative to its historical range.
Company is effectively debt-free after netting cash.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 24, 2026
Key Insights: Guardant Health, Inc. Common Stock (GH)
Composite verdict for Guardant Health, Inc. Common Stock: Robust financial health and a strong balance sheet are offset by a lack of profitability and negative free cash flow, while the company's valuation trades at an elevated level relative to its historical range.. Piotroski F-Score of 5/9 indicates mixed fundamentals for Guardant Health, Inc. Common Stock. Altman Z-Score of 4.93 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -3.21 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 27% annually — a strong growth profile.
- Free-cash-flow margin is negative (-22%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -151.0× leaves little room for earnings shocks.
- Guardant Health, Inc. Common Stock posted a net loss in 8 of 8 available completed fiscal years (2018–2025).
- At a valuation score of 20/100, GH trades at a premium to its historical multiples.
See how GH ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all GH moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 21 | Regular | 173.39 | -3.34% | -2.23 |
| Sep 21 | After-hours | 173.87 | -3.07% | -2.05 |
Frequently Asked Questions about GH
Is GH stock a buy right now?
PreMarketPrice's quantitative model rates Guardant Health, Inc. Common Stock's financial health at 75/100 — Robust financial health and a strong balance sheet are offset by a lack of profitability and negative free cash flow, while the company's valuation trades at an elevated level relative to its historical range.. This is a data-driven snapshot of fundamentals, not investment advice.
Is GH stock overvalued?
Guardant Health, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Guardant Health, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for GH. The Earnings section lists recent reports and updates as dates are announced.
What sector does Guardant Health, Inc. Common Stock operate in?
Guardant Health, Inc. Common Stock operates in the Healthcare sector, within the Services-Medical Laboratories industry. The Related Stocks section lists sector peers for comparison.
What does Guardant Health, Inc. Common Stock do?
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use.
About Guardant Health, Inc. Common Stock (GH) Stock
Guardant Health, Inc. Common Stock (GH) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry. Real-time pricing data for Guardant Health, Inc. Common Stock is available on this page with a market capitalization of $23.5 billion. The financial health score for GH is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for GH stock.
GH Stock Analysis & Key Metrics
On PreMarketPrice, you can track Guardant Health, Inc. Common Stock (GH) across multiple dimensions:
- Pre-market price & movement: Real-time GH stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for GH with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Guardant Health, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for GH.
- Sector peers: Compare GH against 10 other healthcare stocks on key financial metrics.
Is GH a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Guardant Health, Inc. Common Stock (GH) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Guardant Health, Inc. Common Stock (GH) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.